Treatment for glioblastoma (GBM)
Intended for US audiences only.

Downloads and videos

Educational resources

In this section, you'll find a variety of resources to help you better understand how Optune® treats glioblastoma and how to manage Optune. Many of these materials can be printed and shared with your family, caregivers, and healthcare team.

First glance at Optune

Answers common questions about starting Optune, an FDA-approved treatment for GBM.

View this PDF Ver este PDF

Understanding Optune

A comprehensive guide about how Optune works and how to integrate treatment into everyday life.

View this PDF Ver este PDF

Patient Scalp Care Guidelines

An educational guide which answers questions about scalp care and transducer array placement.

View this PDF Ver este PDF

nCompass support brochure

Learn more about the support available from the moment your doctor prescribes Optune.

View this PDF

Optune Insights

A resource outlining experiences from an Optune user and their caregiver.

View this PDF

Travel Support by nCompass brochure

An overview of nCompass travel support offered before, during, and after your trip.

View this PDF

Patient Information and Operation Manual

Step-by-step directions for using all system components.

View this PDF

Instructions For Use

A closer look at Optune benefits and safety information.

View this PDF

Video library

Watch videos about Optune, how it works, and how other patients and caregivers have integrated Optune into their lives.

Select video category:

Alternate Text Alternate Text

Featured
videos

Alternate Text Alternate Text

Learn about
Optune

Alternate Text Alternate Text

Patient experiences
with Optune

EF-14 Video: Integrating Optune into Daily Life

The health status of patients featured in these videos reflect their condition at the time the videos were recorded and may have changed over time.

Optune users share their experiences

Watch Now

Find an Optune doctor

By ZIP code

What is Optune® approved to treat?

Optune is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.

Newly diagnosed GBM

If you have newly diagnosed GBM, Optune is used together with a chemotherapy called temozolomide (TMZ) if:

Recurrent GBM

If your tumor has come back, Optune can be used alone as an alternative to standard medical therapy if:

Who should not use Optune?

Optune is not for everyone. Talk to your doctor if you have:

Do not use Optune if you are pregnant or are planning to become pregnant. It is not known if Optune is safe or effective during pregnancy.

What should I know before using Optune?

Optune should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure™, the maker of Optune.

What are the possible side effects of Optune?

Most common side effects of Optune when used together with chemotherapy (temozolomide, or TMZ) were low blood platelet count, nausea, constipation, vomiting, tiredness, scalp irritation from the device, headache, seizure, and depression.

The most common side effects when using Optune alone were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers.

Talk to your doctor if you have any of these side effects or questions.


Please click here to see the Optune Instructions for Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

On this site, patient and healthcare professional videos as well as all images labeled as Optune users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals. All other depictions of patients and caregivers are actor portrayals.

What is Optune approved to treat?

Optune is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.